Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Hologic, Inc’s stock clocked out at $67.29, up 1.45% from its previous closing price of $66.33. In other words, the price has increased by $1.45 from its previous closing price. On the day, 2.05 million shares were traded. HOLX stock price reached its highest trading level at $67.62 during the session, while it also had its lowest trading level at $65.5.
Ratios:
To gain a deeper understanding of HOLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.06. For the most recent quarter (mrq), Quick Ratio is recorded 2.81 and its Current Ratio is at 3.55. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.52.
On August 06, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $87. Citigroup Upgraded its Neutral to Buy on July 09, 2025, while the target price for the stock was maintained at $80.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 22 ’25 when MACMILLAN STEPHEN P bought 138,358 shares for $66.98 per share.
Madaus Martin D bought 5,445 shares of HOLX for $300,760 on May 07 ’25. The Director now owns 5,445 shares after completing the transaction at $55.24 per share. On Dec 04 ’24, another insider, Mitchell Essex D, who serves as the Chief Operating Officer of the company, sold 24,856 shares for $76.34 each. As a result, the insider received 1,897,482 and left with 27,957 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HOLX now has a Market Capitalization of 14966593536 and an Enterprise Value of 15605793792. As of this moment, Hologic,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.92, and their Forward P/E ratio for the next fiscal year is 14.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.71 while its Price-to-Book (P/B) ratio in mrq is 3.09. Its current Enterprise Value per Revenue stands at 3.864 whereas that against EBITDA is 12.498.
Stock Price History:
The Beta on a monthly basis for HOLX is 0.63, which has changed by -0.17140746 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, HOLX has reached a high of $84.39, while it has fallen to a 52-week low of $51.90. The 50-Day Moving Average of the stock is 1.23%, while the 200-Day Moving Average is calculated to be 3.41%.
Shares Statistics:
It appears that HOLX traded 2.06M shares on average per day over the past three months and 3026280 shares per day over the past ten days. A total of 222.22M shares are outstanding, with a floating share count of 220.46M. Insiders hold about 0.88% of the company’s shares, while institutions hold 100.83% stake in the company. Shares short for HOLX as of 1756425600 were 3121377 with a Short Ratio of 1.51, compared to 1753920000 on 4413873. Therefore, it implies a Short% of Shares Outstanding of 3121377 and a Short% of Float of 1.8499999999999999.
Earnings Estimates
The firm’s stock currently is rated by 16.0 analysts. The consensus estimate for the next quarter is $1.08, with high estimates of $1.18 and low estimates of $1.02.
Analysts are recommending an EPS of between $4.26 and $4.19 for the fiscal current year, implying an average EPS of $4.24. EPS for the following year is $4.52, with 20.0 analysts recommending between $4.61 and $4.37.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $1.03B. It ranges from a high estimate of $1.04B to a low estimate of $1.03B. As of the current estimate, Hologic, Inc’s year-ago sales were $987.9MFor the next quarter, 15 analysts are estimating revenue of $1.07B. There is a high estimate of $1.09B for the next quarter, whereas the lowest estimate is $1.05B.
A total of 19 analysts have provided revenue estimates for HOLX’s current fiscal year. The highest revenue estimate was $4.09B, while the lowest revenue estimate was $4.08B, resulting in an average revenue estimate of $4.09B. In the same quarter a year ago, actual revenue was $4.03BBased on 19 analysts’ estimates, the company’s revenue will be $4.27B in the next fiscal year. The high estimate is $4.31B and the low estimate is $4.22B.
